Béfizal

Small molecule

Béfizal is one of 5 small molecule programs targeting Leber hereditary optic neuropathy. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Leber Hereditary Optic NeuropathyActive, not recruiting

Leber Hereditary Optic NeuropathyPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Leber Hereditary Optic Neuropathy

#DrugCompanyPhaseTrials

Curcumin

Neoral

1 3

Avicel

SSanthera Pharmaceuticals

Raav2-ND4

1 5

Béfizal

HHôpital Necker-Enfants Malades

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Leber hereditary optic neuropathy1 trial

Trial of Befizal® 200 mg for the Treatment of Leber Hereditary Optic Neuropathy

Completed·HHôpital Necker-Enfants Malades·Phase 2/3·NCT04561466·14 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Béfizal. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Béfizal compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Béfizal. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hôpital Necker-Enfants Malades company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: HHôpital Necker-Enfants Malades

Béfizal

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Leber hereditary optic neuropathy1 trial

References

Drug Info

Quick Facts

Related News